Literature DB >> 7572626

The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy.

M P Ryan1, J G Cleland, J A French, J Joshi, L Choudhury, L Chojnowska, E Michalak, S al-Mahdawi, P Nihoyannopoulos, C M Oakley.   

Abstract

Phenotypic heterogeneity in hypertrophic cardiomyopathy (HC) makes definitive diagnosis difficult, particularly during family screening. We studied the electrocardiogram (ECG) as a potential initial screening test in patients with HC. Using accepted diagnostic criteria, we examined the ECGs and echocardiograms of 159 patients with a confirmed clinical or genetic diagnosis of HC. An abnormal ECG was found in 154 patients (97%) while only 146 (92%) showed an abnormal echocardiogram. Of the former, 9 patients (6%) had normal echocardiograms and had been diagnosed on the basis of identification of a mutation in the beta myosin heavy chain gene (n = 8) or obligate carrier status (n = 1). Only 1 of these 9 patients was under age 20, the time at which hypertrophy is normally expressed on the echocardiogram. The remaining 5 patients (3%) without ECG abnormality consisted of 1 patient with an echocardiogram clearly diagnostic of HC and 4 clinically normal patients (aged 13, 24, 29, and 33 years) with normal echocardiograms who had been diagnosed by mutation identification (n = 3) or obligate carrier status (n = 1). Thus only these latter 4 patients (3%) would not have been diagnosed as having HC based on an abnormal ECG and/or abnormal echocardiogram. Screening relatives for HC by ECG criteria alone detects all those whom an echocardiogram will diagnose. While echocardiography aids in the specificity of HC diagnosis, the ECG, within the context of a family with a proven case of HC, is a more sensitive marker of the disease. It is therefore both a cost-effective and useful tool for screening those to proceed to echocardiography.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572626     DOI: 10.1016/s0002-9149(99)80198-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

1.  The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited.

Authors:  B J Maron
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-10       Impact factor: 1.468

2.  Normal Variant T-Wave Changes in an Athlete with Structurally Normal Cardiac Anatomy and Function.

Authors:  Adam M Noyes; Peter Schulman
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-07-14       Impact factor: 1.468

Review 3.  Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review.

Authors:  Kimberly G Harmon; Irfan M Asif; Joseph J Maleszewski; David S Owens; Jordan M Prutkin; Jack C Salerno; Monica L Zigman; Rachel Ellenbogen; Ashwin L Rao; Michael J Ackerman; Jonathan A Drezner
Journal:  Circulation       Date:  2015-05-14       Impact factor: 29.690

4.  Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy.

Authors:  Neal K Lakdawala; Jens Jakob Thune; Barry J Maron; Allison L Cirino; Ole Havndrup; Henning Bundgaard; Michael Christiansen; Christian M Carlsen; Jean-François Dorval; Raymond Y Kwong; Steven D Colan; Lars V Køber; Carolyn Y Ho
Journal:  Am J Cardiol       Date:  2011-09-21       Impact factor: 2.778

Review 5.  Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis.

Authors:  Angie Mae Rodday; John K Triedman; Mark E Alexander; Joshua T Cohen; Stanley Ip; Jane W Newburger; Susan K Parsons; Thomas A Trikalinos; John B Wong; Laurel K Leslie
Journal:  Pediatrics       Date:  2012-03-05       Impact factor: 7.124

6.  [Sudden cardiac death in athletes and its prevention].

Authors:  T Tönnis; C Tack; K-H Kuck
Journal:  Herz       Date:  2015-05       Impact factor: 1.443

Review 7.  Gelsolin superfamily proteins: key regulators of cellular functions.

Authors:  P Silacci; L Mazzolai; C Gauci; N Stergiopulos; H L Yin; D Hayoz
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

Review 8.  The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice.

Authors:  Iacopo Olivotto; Francesca Girolami; Stefano Nistri; Alessandra Rossi; Luigi Rega; Francesca Garbini; Camilla Grifoni; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-27       Impact factor: 4.132

9.  Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy.

Authors:  Katsuharu Uchiyama; Kenshi Hayashi; Noboru Fujino; Tetsuo Konno; Yuichiro Sakamoto; Kenji Sakata; Masa-aki Kawashiri; Hidekazu Ino; Masakazu Yamagishi
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

10.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.

Authors:  J Malcom; O Arnold; Jonathan G Howlett; Anique Ducharme; Justin A Ezekowitz; Martin J Gardner; Nadia Giannetti; Haissam Haddad; George A Heckman; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.